SynthesisFrontiers in oncology2025
Efficacy of TACE plus tyrosine kinase inhibitors and immune checkpoint inhibitors in patients with unresectable hepatocellular carcinoma: a systematic review and meta-analysis.
Synthesis in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The impact of comorbid type 2 diabetes on survival outcomes in patients with solid tumors treated with immune checkpoint inhibitors: a meta-analysis focusing on lung cancer.Frontiers in endocrinology · 2026Pooled it
- A transcriptomic five-gene signature for sorafenib response prediction in hepatocellular carcinoma: clinical promise and limitations.Journal of gastrointestinal oncology · 2026Article
- Stage-Dependent Efficacy of TACE Combined with Tyrosine Kinase and Immune Checkpoint Inhibitors as Conversion Therapy for Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Study.Journal of hepatocellular carcinoma · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Transarterial chemoembolization (TACE) is currently widely used in the treatment of patients with unresectable hepatocellular carcinoma. However, the combination of TACE with tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors (ICIs) during treatment remains controversial. This study aims to evaluate the efficacy and safety of TACE combined with TKIs and ICIs in patients with unresectable hepatocellular carcinoma and to compare this approach with other treatment regimens. Method: We conducted a systematic search of relevant studies from multiple online databases, with the search deadline set at March 2025. We explored the relationship between prognosis and adverse reactions of TACE + TKIs + ICIs combination therapy, TACE + TKIs therapy, and TACE monotherapy in patients with unresectable hepatocellular carcinoma. Based on heterogeneity assessment results, we used fixed- or random-effects models and employed trial sequential analysis (TSA) to determine whether the findings have sufficient conclusive power. Result: This study included 24 cohort studies involving 3,906 patients. Compared with TACE plus TKIs therapy and TACE monotherapy, the combination therapy of TACE plus TKIs plus ICIs significantly improved the objective response rate (ORR) (risk ratio [RR] = 1.49 [95% confidence interval [CI] = 1.35-1.63], Conclusion: This study demonstrates that, compared with TACE combined with TKIs and TACE monotherapy, TACE + TKIs + ICIs combination therapy can substantially improve the prognosis of patients with unresectable hepatocellular carcinoma while maintaining a manageable safety profile. Systematic Review Registration: https://www.crd.york.ac.uk/prospero/, identifier PROSPERO CRD420250653604.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.